Schizophrenia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Schizophrenia Clinical Trials Market Report Overview
The Schizophrenia clinical trial market research report provides an overview of the Schizophrenia Clinical trials scenario. This report provides top-line data relating to the clinical trials on Schizophrenia and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. It provides prominent drugs for in-progress trials (based on the number of ongoing trials).
Key Regions | · North America
· Asia-Pacific · Europe · Middle East & Africa · South & Central America |
Key Countries | · The US
· China · India · Russia · Japan · Germany · Iran · The UK · Spain · South Korea |
Key Sponsor Types | · Institution
· Company · Government |
Leading Sponsors | · Johnson & Johnson
· Otsuka Holdings Co Ltd · AstraZeneca Plc · Pfizer Inc · The Lundbeck Foundation · Sumitomo Chemical Co Ltd · Eli Lilly and Co · Collaborative Neuroscience Network LLC · Novartis AG · F. Hoffmann-La Roche Ltd |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Schizophrenia Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Schizophrenia clinical trials market are North America, Asia-Pacific, Europe, the Middle East & Africa, and South & Central America, among others. North America dominates the market as of June 2023.
In a country-wise analysis, as of June 2023, the US has the highest number of Schizophrenia clinical trials, followed by China, India, Russia, Japan, Germany, Iran, the UK, Spain, and South Korea.
E7 countries: The key countires in E7 include Brazil, Russia, India, China, Mexico, Turkey, and Indonesia. Among the E7 Russia has the highest proportion of Schizophrenia to Central Nervous System clinical trials as of June 2023. Out of all the clinical trials conducted in the E7 countries, the majority were in China.
G7 countries: The G7 is a group of United States, United Kingdom, Germany, France, Italy, Canada, and Japan. Among the G7, Japan has the highest proportion of Schizophrenia to Central Nervous System clinical trials as of June 2023. Moreover, most of the clinical trials were conducted in the US.
Schizophrenia Clinical Trials Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights into the Schizophrenia Clinical Trials Market, Download a Free Report Sample
Schizophrenia Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Schizophrenia clinical trials market are institution, company, and the government. Out of them, the company sponsor type dominates the market.
Schizophrenia Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
Buy the Full Report for More Sponsor Type Insights into the Schizophrenia Clinical Trials Market, Download a Free Report Sample
Schizophrenia Clinical Trials Market - Competitive Landscape
The leading sponsors in the Schizophrenia clinical trials market are Johnson & Johnson, Otsuka Holdings Co Ltd, AstraZeneca Plc, Pfizer Inc, The Lundbeck Foundation, Sumitomo Chemical Co Ltd, Eli Lilly and Co, Collaborative Neuroscience Network LLC, Novartis AG, and F. Hoffmann-La Roche Ltd. Johnson & Johnson led the Schizophrenia clinical trials market in June 2023.
Schizophrenia Clinical Trials Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for More Companies Insights into the Schizophrenia Clinical Trials Market, Download a Free Report Sample
Segments Covered in the Report
Schizophrenia Clinical Trials Regional Outlook (2023)
- North America
- Asia-Pacific
- Europe
- Middle East & Africa
- South & Central America
Schizophrenia Clinical Trials Country Outlook (2023)
- The US
- China
- India
- Russia
- Japan
- Germany
- Iran
- The UK
- Spain
- South Korea
Schizophrenia Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with a reason for unaccomplishment
- The report provides enrollment trends for the past five years
- Report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regard to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Otsuka Holdings Co Ltd
AstraZeneca Plc
Pfizer Inc
The Lundbeck Foundation
Sumitomo Chemical Co Ltd
Eli Lilly and Co
Collaborative Neuroscience Network LLC
Novartis AG
F. Hoffmann-La Roche Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
Which is the leading region in the Schizophrenia clinical trials market?
North America is the leading region in the Schizophrenia clinical trials market as of June 2023.
-
Which is the leading country in the Schizophrenia clinical trials market?
The US is the leading country in the Schizophrenia clinical trials market as of June 2023.
-
Which is the leading sponsor type in the Schizophrenia clinical trials market?
Company is the leading sponsor type in the Schizophrenia clinical trials market as of June 2023.
-
Which is the leading sponsor type in the Schizophrenia clinical trials market?
Company is the leading sponsor type in the Schizophrenia clinical trials market as of June 2023.
-
Who are the leading sponsors in the Schizophrenia clinical trials market?
The leading sponsors in the Schizophrenia clinical trials market are Johnson & Johnson, Otsuka Holdings Co Ltd, AstraZeneca Plc, Pfizer Inc, The Lundbeck Foundation, Sumitomo Chemical Co Ltd, Eli Lilly and Co, Collaborative Neuroscience Network LLC, Novartis AG, and F. Hoffmann-La Roche Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.